Cellegy Savvy HIV prevention trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cellegy's Phase III HIV prevention trial of the microbicide Savvy (C31G vaginal gel) has reached 50% enrollment, the firm announces March 3. Cellegy estimates 1,500 women have enrolled in the Ghana-based trial since initiation in March 2004. A second trial is underway in Nigeria; both are slated to complete in late 2006. A third study is being conducted in the U.S. and has enrolled 200 patients. Cellegy claims Savvy is the most advanced microbicide in development for HIV prevention. "Savvy has also shown activity that suggests protection against...herpes simplex virus, chlamydia, trichomonas, gonorrhea and syphilis," the firm notes. Cellegy's Biosyn subsidiary is conducting the Savvy trials...